HHS Will Not Use March-In Rights For Remdesivir

The administration says it will only use march-in rights to lower the cost of COVID-19 drugs if all a product’s patents are owned by the federal government, which is not the case for remdesivir. The administration’s stance is in direct opposition to that of a bipartisan group of 34 state attorneys general that recently called on the government to either use its march-in rights or allow states to sidestep patents to lower the cost of the antiviral, which hospitals are...